Clinical trial
Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in…
NCT00277810 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00277810 |
|---|---|
| Title | Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease |
| Official title | A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study of 3 Doses of Lecozotan (SRA-333) SR in Outpatients With Mild to Moderate Alzheimer's Disease Treated With a Cholinesterase Inhibitor |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | lecozotan SR (SRA-333) |
| Enrollment | 250 |
| Start date | Mar 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Jan 16, 2006 |
| Last update posted | Jul 7, 2020 |
| Countries | Argentina, Australia, Canada, Finland, France, Italy, Poland, South Africa, Spain, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: